| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3554 |
| Trial ID | NCT05993949 |
| Disease | Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-X19|Tecartus|Brexucabtagene autoleucel |
| Co-treatment | Dasatinib |
| Location approved | US, EU, UK, Australia, Canada |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia |
| Year | 2023 |
| Country | United States |
| Company sponsor | Stanford University |
| Other ID(s) | IRB-68603 |
| Cohort 1 | |||||||
|
|||||||